Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.
Latest Information Update: 09 Oct 2019
At a glance
- Drugs Cilastatin (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions; First in man
- Sponsors Spherium Biomed
Most Recent Events
- 09 Oct 2019 New trial record
- 05 Oct 2019 Results published in the Spherium Biomed Media Release
- 05 Oct 2019 According to a Spherium Biomed mdia release, the company announces the completion of this study.